US-based medical diagnostics technology developer Enlitic raised $10m in a series B round led by radiology services provider Capitol Health on Tuesday.
Founded in August 2014, Enlitic uses machine learning to analyse x-ray images in order to identify ailments such as lung cancer at an early-stage, increasing a patient’s odds of survival, while at the same time reducing the occurrence of false positives.
Australia-based Capitol Health will support Enlitic’s expansion into Australia and Asia as part of the deal, integrating the technology into its own radiology products.
The funding will also support Enlitic’s aim to map the entire human body and extend the diseases the technology can identify.
Amplify Partners, Data Collective and assorted angel investors had previously provided $5m funding for Enlitic. Part of that funding was originally reported as a $2m seed round in October 2014, but clarified by chief executive Jeremy Howard to Wall Street Journal yesterday.